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INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA) infections are challenging to treat in an era of increasing antimicrobial resistance. Due to increased drug resistance, very limited treatment options are available. Patients admitted in hospitals with open wounds, invasive devices, and immunocompromised are at greater risk with MRSA infection. Furthermore, the emergence of highly virulent community-associated MRSA causing skin infections, sepsis, toxic shock syndrome, and necrotizing pneumonia is the another concern. [1] For treatment of multidrug-resistant MRSA, glycopeptides such as vancomycin and teicoplanin are considered the drug of choice. [2] Since the emergence of vancomycin resistance in enterococci in 1988 and its in vitro demonstration that its resistance genes (Van A and Van B) are transmissible to other bacterial species including S. aureus, the emergence of vancomycin-intermediate-resistant S. aureus and vancomycin-resistant S. aureus in the clinical sample has become a great concern. [3] For the treatment of this MRSA infection, newer drugs such as ceftaroline, dalbavancin, oritavancin, and tedizolid are available. This antimicrobial agent binds to penicillin-binding proteins (PBP) inhibiting cell wall synthesis and has a high affinity for PBP 2a, which is associated with methicillin resistance. The ability of ceftaroline to bind the PBP 2a, an MRSA-specific protein, makes it unique among cephalosporin. Ceftaroline is consistently active against multidrug-resistant Streptococcus pneumoniae, S. aureus, and some Gram-negative organisms. As ceftaroline is a newer agent with only limited knowledge about its susceptibility pattern, the present study was conducted to know the in vitro activity of ceftaroline against MRSA.
MATERIALS AND METHODS
A total of thirty nonduplicate methicillin-resistant S. aureus strains isolated from various clinical samples were included in the study. Methicillin resistance was detected using cefoxitin 30-μg disc. Ceftaroline minimum inhibitory concentrations (MIC) were detected for all the thirty isolates using ceftaroline E-strips (Biomerieux). The Clinical and Laboratory Standards Institute clinical break points were applied for interpretation of ceftaroline MIC (sensitive ≤1 μg/ml, 2 μg/ml intermediate, and resistant ≥ 4 μg/ml). S. aureus ATCC 29213 was used as a control strain for MIC detection.
RESULTS
Of 30 MRSA isolates tested, 28 (93.3%) were sensitive to ceftaroline. Ceftaroline MIC values ranged from 0.25 to 4 μg/ml. One isolate with intermediate susceptibility showed MIC of 2 μg/ml. Moreover, one isolate resistant to ceftaroline showed MIC of 4 μg/ml. All the remaining isolates showed MIC ≤1 μg/ml. The MIC50 and MIC90 of the isolates were 0.38 μg/ml and 0.75 μg/ml, respectively [ Table 1 ].
All thirty isolates of MRSA were sensitive to linezolid, teicoplanin, and tigecycline by Kirby-Bauer disc diffusion method [ Table 2 ].
All isolates showed 100% susceptibility to vancomycin, while ceftaroline susceptibility was 93.33% [ Figure 1 ].
DISCUSSION
In this study, 28 MRSA (93.33%) isolates were sensitive to ceftaroline with the MIC90 being 0.75 μg/ml. These findings correlate well with the surveillance studies. In the Assessing Worldwide Antimicrobial Resistance Evaluation [4] program, 98.4% of the MRSA were inhibited at MIC value of 1 μg/ml. The highest MIC in their study was 2 μg/ml. In a study by Jones et al., 94.8% of the MRSA isolates from the USA were inhibited at a concentration of 1 μg/ml, whereas only 82.6% European isolates were inhibited at 1 μg/ml. [5] In the study conducted by Basireddy et al., [6] 50 MRSA isolates were sensitive to ceftaroline. Ceftaroline MIC values ranged from 0.125 to 1.5 mg/L. Only two isolates showed the maximum MIC of 1.5 mg/L, which is in the intermediate susceptible range. Similarly, this study showed MIC range from 0.25 to 4 μg/ml, of which one isolate with intermediate susceptibility showed MIC of 2 μg/ml and one isolate resistant to ceftaroline showed MIC of 4 μg/ml. Moreover, all the remaining isolates showed MIC ≤1 μg/ml. Furthermore, a study conducted by Vidaillac et al. found that MIC ranged between 0.125 and 2 μg/ml for ceftaroline. [7] The MIC50 and MIC90 of the isolates in the study conducted by Basireddy et al. [6] were 0.5 and 1 mg/L, respectively, which was similar to our study.
A study conducted by Vidaillac et al. found that MIC ranged between 0.5 and 2 μg/ml for vancomycin. [7] While MIC of vancomycin was found to be <2 μg/ml for all isolates in this study Ho et al. reported series of six patients, in which ceftaroline was utilized as salvage monotherapy in persistent MRSA bacteremia or endocarditis. All six patients experienced rapid clearance of MIC: Minimum inhibitory concentration their bacteremia after starting ceftaroline suggesting sterilization within 13 days of starting ceftaroline. [8] Advancement of modern medicine may have prolonged the lifespan of man, but it has also brought problems such as "Drug resistance." The spread of superbugs in the community might mean the "End of Antibiotic Era." It is with a view to increase awareness in the health-care community that the WHO declared following slogan in 2011 -"No action today, no cure tomorrow."
CONCLUSION
MRSA continues as a major problem in the community.
Vancomycin remains the gold-standard treatment option for MRSA infections. The pattern of antibiotic use for MRSA has significantly changed over the past 10 years limiting their use suggesting the need for newer antimicrobials. Considering patient-specific parameters, cost and relevant clinical data demonstrating drug safety and efficacy should be employed for the selection of the appropriate alternative agent. The approval of ceftaroline fosamil for MRSA provides a new empirical option that addresses the need to cover today's infections while preserving the well-recognized tolerability profile of the cephalosporin class. Ceftaroline showed good in vitro activity against MRSA isolates and can be considered an effective alternative for the treatment of these infections.
Financial support and sponsorship
Nil.
